The emergence of regenerative therapy presents promise for treating erectile dysfunction (ED), offering an approach that targets the underlying physiological mechanisms. Evidence indicates that regenerative therapies like low-intensity shock wave therapy (LISWT), stem cell therapy (SCT), and platelet-rich plasma (PRP) injections may enhance erectile function by stimulating tissue regeneration, improving blood flow, and restoring nerve function. These therapies have demonstrated effectiveness in some clinical trials, with some patients experiencing significant improvements in erectile function and overall sexual satisfaction. However, several important limitations exist in these clinical trials, particularly concerning the heterogeneity in patient selection or treatment protocol, small sample sizes, short follow-up periods, reliance on subjective rather than objective outcome measures, and variability in basic clinical parameters among the patients involved. Consequently, these trials are considered to provide low-quality evidence and have not garnered clear recommendations from medical societies. Although some evidence supports LISWT, it remains of low quality, while SCT and PRP are still considered investigational or experimental. Future studies that address these highlighted shortcomings will establish stronger evidence and provide better guidance for clinical practice.